Formulation and Delivery of Mitragynine: A Mini Review

Satyajit D. Sarker; Lutfun Nahar

doi:10.53941/jmnp.2025.100020

Abstract

Mitragynine is the most abundant psychoactive indole alkaloid found in the leaves of Mitragyna speciosa, which is commonly known as “Kratom”, and is distributed widely in Indonesia, Malaysia, Papua New Guinea, the Philippines, and Thailand. The leaves of M. speciosa are prepared for oral consumption and typically involve dried leaves that are brewed into tea or ground and placed into capsules. Additionally, M. speciosa is also used as a leaf poultice to treat fever, diarrhoea and for wound healing. In addition to peroral delivery, mitragynine could also be delivered through nasal and transdermal routes. The application of nanotechnology has been found to enhance the delivery of mitragynine and thus to enhance its therapeutic efficacy. This mini review, for the first time, presents a critical appraisal of the available literature on the formulation and delivery of mitragynine.

References

1.
Brown, P.N.; Lund, J.A.; Murch, S.J. A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom. J. Ethnopharmacol. 2017, 202, 302–325.
2.
Annuwar, N.A.K.; Azlam, U.K.; Mediani, A; et al. An insight review on the neuropharmacological effects, mechanisms of action, pharmacokinetics and toxicity of mitragynine. Biomed. Pharmacother. 2024, 171, 116134.
3.
Alford, A.S.; Moreno, H.L.; Benjamin, M.M.; et al. Exploring the therapeutic potential of mitragynine and corynoxeine: Kratom-derived indole and oxindole alkaloids for pain management. Pharmaceuticals 2025, 18, 222.
4.
Das, J. Kratom alkaloids for the treatment of alcohol use disorder. ACS Chem. Neurosci. 2024, 15, 4352–4359.
5.
Garza-Garcia, J.J.O.; Qu, Y. Chemical, pharmacological properties and biosynthesis of opioid mitragynine in Mitragyna speciosa (kratom). Curr. Opin. Plant Biol. 2024, 81, 102600.
6.
Begum, T.; Arzmi, M.H.; Khatib, A.; et al. A review on Mitragyna speciosa (Rubiaceae) as a prominent medicinal plant based on ethnobotany, phytochemistry and pharmacological activities. Nat. Prod. Res. 2024, 39, 1636–1652.
7.
Ernawati, T.; Hermawan, F.; Kusumaningrum, S. A review on isolation, characterization, biosynthesis, synthesis, modification, pharmacological activities and toxicology of mitragynine. Gazi Univ. J. Sci. 2024, 37, 1654–1672.
8.
Bachu, A.K.; Singal, P.; Griffin, B.; et al. Kratom use and mental health: A systematic literature review and case example. J. Addictive Dis. 2024, 42, 301–312.
9.
Karunakaran, T.; Ngew, K.Z.; Zailan, A.A.D.; et al. The chemical and pharmacological properties of mitragynine and its diastereomers: An insight review. Front. Pharmacol. 2022, 13, 805986.
10.
Harun, N.; Kamaruzzaman, N.A.; Sofian, Z.M.; et al. Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy. Neurosci. Lett. 2022, 773, 136500.
11.
Sengnon, N.; Vonghirundecha, P.; Chaichan, W.; et al. Seasonal and geographic variation in alkaloid content of kratom (Mitragyna speciosa (Korth.) Havil.) from Thailand. Plants 2023, 12, 949.
12.
Leksungnoen, N.; Andriyas, T.; Ngernsaengsaruay, C.; et al. Variations in mitragynine content in the naturally growing Kratom (Mitragyna speciosa) population of Thailand. Front. Plant Sci. 2022, 13, 1028547.
13.
Warner, M.L.; Kaufman, N.C.; Grundmann, O. The pharmacology and toxicology of kratom: From traditional herb to drug of abuse. Int. J. Legal Med. 2016, 130, 127–138.
14.
Leksungnoen, N.; Andriyas, T.; Tansawat, R.; et al. Higher accumulation of mitragynine in Mitragyna speciosa (kratom) leaves affected by insect attack. PLoS ONE 2025, 20, e0320941.
15.
Leksungnoen, N.; Andriyas, T.; Ku-Or, Y.; et al. The effect of light intensity and polyethylene-glycol-induced water stress on the growth, mitragynine accumulation, and total alkaloid content of kratom (Mitragyna speciosa). Horticulture 2025, 11, 272.
16.
Sudmoon, R.; Tanee, T.; Wonok, W.; et al. Discovery of rhynchophylline and mitraphylline in two Thai Mitragyna species and the investigation of their biological activity via opioid gene expression analysis. Sci. Rep. 2025, 15, 5865.
17.
Ramanathan, S.; Parthasarathy, S.; Murugaiyah, V.; et al. Understanding the physicochemical properties of mitragynine, a principal alkaloid of Mitragyna speciosa, for preclinical evaluation. Molecules 2015, 20, 4915–4927.
18.
Azhar, S.N.A.S.; Ashari, S.E.; Tan, J.K.; et al. Screening and selection of formulation components of nanostructured lipid carriers system for Mitragyna speciosa (Korth). Havil drug delivery. Ind. Crops Prod. 2023, 198, 116668.
19.
Anantaworasakul, P.; Preedalikit, W.; Anantaworasakul, P.; et al. Phytochemical characterization, bioactivities and nanoparticle-based topical gel formulation development from four Mitragyna speciosa varieties. Gels 2025, 11, 494.
20.
Zhao, S.M.; Zhao, H.; Zuo, J.Y.; et al. Evaluation of drug permeability across Ex vivo nasal mucosa: A simulation-based approach to minimize thickness-related variability. J. Drug Delivery Sci. Technol. 2025, 108, 106959.
21.
Tabboon, P.; Limpongsa, E.; Tuntiyasawasdikul, S.; et al. Screening the potential of pharmaceutical liquids on enhancing dissolution, intestinal permeation, and stability of Mitragyna speciosa bioactive for peroral delivery systems. Ind. Crops Prod. 2025, 225, 120525.
22.
Thepthong, P.; Srirat, S.; Hiranrat, W.; et al. Development of chitosan-based microencapsulation system for Mitragyna speciosa alkaloids: A novel approach for alzheimer's disease treatment. J. Pharm. Innov. 2025, 20, 58.
23.
Singh, M.N.; Hemant, K.S.Y.; Ram, M.; et al. Microencapsulation: A promising technique for controlled frug delivery. Research in Pharmaceutical Sciences 2010, 5, 65–77.
24.
Tomaro-Duchesneau, C.; Saha, S.; Malhotra, M.; et al. Microencapsulation for the therapeutic delivery of drugs, live mammalian and bacterial cells, and other biopharmaceutics: Current status and future directions. J. Pharm. 2012, 2013, 103527.
25.
Zhao, L.; Chen, J.; Bai, B.; et al. Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing. Front. Pharmacol. 2024, 14, 1333986.
26.
Roberts, M.S.; Cheruvu, H.S.; Mangion, S.E.; et al. Topical drug delivery: History, percutaneous absorption, and product development. Adv. Drug Delivery Rev. 2021, 177, 113929.
27.
Tuntiyasawasdikul, S.; Junlatat, J.; Tabboon, P.; et al. Mitragyna speciosa ethanolic extract: Extraction, anti-inflammatory, cytotoxicity, and transdermal delivery assessments. Ind. Crops Prod. 2024, 208, 117909.
28.
Djupesland, P.G. Nasal drug delivery devices: Characteristics and performance in a clinical perspective – A review. Drug Delivery Transl. Res. 2013, 3, 42–62.
29.
Sood, A.; Panchagnula, R. Peroral route: An opportunity for protein and peptide drug delivery. Chem. Rev. 2001, 101, 3275–3303.
30.
Khan, S.; Sharma, A.; Jain, V. An overview of nanostructured lipid carriers and its application in drug delivery through different routes. Adv. Pharm. Bull. 2022, 13, 446–460.
31.
Chauhan, I.; Yasir, M.; Verma, M.; et al. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Asvanced Pharm. Bull. 2020, 10, 150–165.
32.
Matra, M.; Phupaboon, S.; Totakul, P.; et al. Microencapsulation of Mitragyna leaf extracts to be used as a bioactive compound source to enhance in vitro fermentation characteristics and microbial dynamics. Anim. Biosci. 2023, 37, 74–83.
33.
Sim, Y.S.; Chong, Z.Y.; Azizi, K.; et al. Development and validation of a gradient HPLC-UV method for mitragynine following in vitro skin permeation studies. J. Chromatogr. B 2022, 1204, 123316.
34.
Peace, M.R.; Smith, M.E.; Poklis, J.L. The analysis of commercially available natural products recommended for use in electronic cigarettes. Rapid Commun. Mass Spectrom. 2020, 34, e8771.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us